WTR Healthcare Happenings

In this episode, Christer Rosen, Founder and CEO of Jupiter Neurosciences (Nasdaq: JUNS), and President & COO Alison Silva join Water Tower Research’s Tim Gerdeman and Healthcare Analyst Robert Sassoon to discuss Jotrol, the company’s proprietary micellar formulation of resveratrol engineered to overcome long‑standing bioavailability and tolerability limitations. Jotrol has demonstrated a ninefold increase in resveratrol bioavailability, enabling therapeutic exposure without the high‑dose GI side effects that have historically constrained the molecule’s therapeutic potential.The team highlights progress on the active Phase 2A Parkinson’s trial enrolling at Georgetown University, designed to evaluate safety, PK, and neuroinflammatory biomarkers, with data expected in early 2027. Management also outlines Jupiter’s dual‑engine strategy spanning clinical development, a consumer longevity brand, and new licensing initiatives including ALA‑002.

In this episode of Healthcare Happenings, Robert Sassoon, WTR healthcare equity analyst, joins host Tim Gerdeman to discuss his initiation of coverage on NurExone Biologic (TSXV: NRX / OTCQB: NRXBF), a preclinical biopharma company advancing a novel exosome platform targeting CNS regeneration. Sassoon walks through the science behind exosome therapeutics, NurExone's differentiated ExoTherapy platform and lead asset ExoP10, which combines a natural exosome carrier with an RNA payload designed to silence the P10 gene and unlock nerve regeneration in acute spinal cord and optic nerve injury. The conversation also covers the company's vertical integration strategy through its Exotop subsidiary and U.S. master cell bank, the LOI with Florida-based BioXTech for GMP manufacturing capacity, and the key milestones investors should track, including IND submission, compassionate use access, first commercial exosome revenue, and a potential U.S. mainboard listing. 

In this episode of Healthcare Happenings, Nick Kadysh, Founding CEO and President of PharmAla Biotech (CSE: MDMA / OTCQB: MDXXF), joins host Tim Gerdeman and WTR healthcare analyst Robert Sassoon to discuss two recently announced transactions. The first is the formation of Restora Neuroscience, a special purpose vehicle created to advance APA01, a non-controlled neurology molecule, through a preclinical partnership with Datiba. The second is a term sheet with Jupiter Neurosciences for the exclusive U.S. licensing of ALA-002, PharmAla's next-generation MDMA therapeutic, in a deal valued at over $100 million in potential milestones and royalties. The conversation covers deal structure, partner selection, key investor milestones across both transactions, and how this partnership-driven model allows PharmAla to advance its pipeline while maintaining its position as a leading global supplier of clinical-grade MDMA. 

In this special episode of the WTR Healthcare Happenings podcast, the second in a two-part series, Professor David Nutt, Chief Science Officer of Solvonis Therapeutics (LSE: SVNS), talks to host Tim Gerdeman and WTR analyst Robert Sassoon about addiction and why he believes Solvonis' novel approach offers potentially better solutions than are currently available. The discussion also covers persistently low AUD treatment penetration, the favorable UK regulatory and reimbursement outlook versus US payer dynamics, how ketamine compares with emerging GLP-1 and psilocybin approaches, and the advantages of Solvonis' AI-enabled drug discovery platform. Finally, Nutt shares his thoughts on where the US federal addiction-research community actually is on psychedelic-assisted treatment for AUD and stimulant use disorder, following his recent presentation at the NIH ( National Institutes of Health) CRAN (Collaborative Research on Addiction) joint council as the sole external speaker on psychedelic therapy for addictions.

In this special episode of Healthcare Happenings, the first in a two‑part series, Anthony Tennyson, CEO of Solvonis Therapeutics (LSE: SVNS), joins host Tim Gerdeman and WTR analyst Robert Sassoon to discuss the company’s strategy in addiction and psychiatry — a field with significant unmet need and limited effective treatment options. Anthony walks through SVN‑001, a ketamine‑based therapy for severe alcohol use disorder now in Phase 3 in the UK, and SVN‑002, a U.S.-focused program targeting the much larger moderate‑to‑severe alcohol use disorder market. He also explains why Solvonis may not yet be fully recognized compared to its U.S.-listed peers. Stay tuned for Part 2 next week with Professor David Nutt, Chief Scientific Officer of Solvonis, who unpacks the neuroscience behind SVN‑001, the search for a better MDMA, and where psychedelic‑assisted addiction therapy is headed.

In this episode of Healthcare Happenings, John Lai, CEO of PetVivo Holdings (PETV), joins host Tim Gerdeman and WTR analyst Robert Sassoon to discuss the company's regenerative medicine platform for companion animals. The conversation covers PetVivo's product suite led by Spryng, its cartilage-mimicking protein particle matrix; the off-the-shelf Precise PRP product; and a BioPiezo collaboration with the University of Connecticut that pairs Spryng with nanofiber technology to drive cartilage regeneration with potential translation to human medicine. Lai also previews the launch of PetVivo.ai, an agentic AI platform for veterinary practices, and outlines the company's pathway toward cash-flow breakeven. 

 In this episode of the WTR Healthcare Happenings podcast, Stephen Rodgers, Head of Global Planning and Strategy at SBC Medical Group Holdings (NASDAQ: SBC), joins WTR’s Tim Gerdeman and Robert Sassoon. Rodgers discusses how SBC’s 26‑year build‑out into a 283‑location platform serving 2.1 million customers with a 72% repeat rate has created a scale, data, and trust advantage that competitors have been unable to replicate. He outlines the rationale for expanding beyond aesthetics into orthopedics, fertility, and dentistry, and highlights longevity as a major white space being addressed through the SBC Wellness 2.0 B2B program. The conversation also covers SBC’s partnership‑driven global expansion via Orange Twist in the U.S., AHH in Singapore, and footholds in Thailand and Vietnam, and concludes with Rodgers’ perspective on AI as a key driver—including plans to leverage SBC’s proprietary library of millions of before‑and‑after treatment images. 

ExoZymes (NASDAQ: EXOZ) CEO Michael Heltzen joins Tim Gerdeman and Robert Sassoon in this episode of the WTR Healthcare Happenings podcast to discuss the company’s AI-driven, cell-free biomanufacturing platform and how it aims to overcome longstanding scalability challenges in synthetic biology. The conversation covers the scientific differentiation of its “exozyme” enzyme engineering approach, the commercial strategy behind its lead programs in metabolic health (NCT) and non-intoxicating cannabinoids, and the broader opportunity to produce high-value molecules that have historically been inaccessible at scale. The podcast also explores regulatory dynamics, near-term commercialization milestones, and ExoZymes’ dual strategy of advancing internal assets while positioning the platform for future licensing, alongside considerations around capital efficiency and funding.

On the latest WTR Healthcare Happenings podcast, we were joined by David Sans, PhD, a healthcare investment banker, and our host, Tim Gerdeman, WTR’s Vice-Chair, Co-Founder, and Chief Marketing Officer. Over the past two years, Sans has focused on a corner of the market most investors overlook: publicly listed companies with low or negative shareholders’ equity and stock prices trading below $1. The conversation covered the tightening Nasdaq listing environment, the mechanics of strategic asset acquisitions and structured financing, the shift in M&A toward asset-level transactions, and a compelling new instrument—clinical trial insurance—that is opening the door to a new class of biotech investors. 

On this episode, Vivos Therapeutics (NASDAQ: VVOS) CEO Kirk Huntsman joins WTR’s Tim Gerdeman and Robert Sassoon on Healthcare Happenings to discuss the company’s 2025 results and the momentum behind its shift from a dentist‑led model to a medically integrated strategy centered on sleep centers and physician referrals, anchored by the Sleep Center of Nevada acquisition. Huntsman highlights strong validation of the new model despite temporary 4Q25 staffing and payer delays, which are now largely resolved. The conversation covers improving patient treatment conversion, infrastructure expansion, rising cardiology and hospital referrals tied to OSA risk, and Vivos’ path toward cash‑flow breakeven by end‑2026. 

Water Tower Research's healthcare equity analyst Robert Sassoon breaks down President Trump's executive order on therapeutic psychedelics, examining the five key mechanisms it puts in place — from accelerated FDA review vouchers and right-to-try expansion to federal funding and ibogaine pathway clearance. Sassoon explains what the order gets right, where it falls short (namely on reimbursement and rescheduling), and which companies — including Compass Pathways, Dephinium Therapeutics, and Helus Pharma — stand to benefit most as the sector gains its first clear federal endorsement as a legitimate therapeutic class. 

In this special preview episode of WTR Healthcare Happenings, Robert Sassoon spotlights two biotechs presenting on Day 1 of the WTR Insights Conference (April 14–15). Nurexone Biologic (TSX-V: NRX | OTCQB: NRXBF) is pioneering an exosome-based therapy for spinal cord injury and other CNS conditions, with Phase 1/2A trials expected to initiate within 12 months. Anixa Biosciences (NASDAQ: ANIX) is advancing a breast cancer vaccine and a novel CAR-T therapy for ovarian cancer — both approaching key clinical inflection points in 2026.  Complimentary for Investors. Register at WaterTowerResearch.com. 

In this episode of the WTR Healthcare Happenings podcast, Water Tower Research’s Shawn Severson and Robert Sassoon are joined by Dr. Paul Sargeant, President and CEO of Circular Genomics, a privately held molecular diagnostics company developing next‑generation blood tests based on circular RNA biomarkers. The conversation explores the science behind circular RNA, the company’s product pipeline, including the pursuit of an out‑licensing strategy, depression assay strategy, and a planned late-2026 launch of its Alzheimer’s research-use-only (RUO) assay;  its systems‑level approach to Alzheimer's beyond the amyloid‑tau model;  Circular Genomics’ commercialization plans, funding strategy, and long-term exit strategy goal.

Robert Sassoon, WTR Senior Healthcare Analyst, joins Tim Gerdeman to discuss obstructive sleep apnea (OSA) and the rapidly evolving treatment landscape for this widespread yet often undiagnosed and potentially fatal condition. The conversation explores the shift away from CPAP amid high non‑adherence rates toward emerging alternatives, including neurostimulation, pharmacotherapy, and oral appliances. Sassoon also highlights the valuation gap between incumbents such as ResMed (NYSE: RMD) and innovators like Vivos Therapeutics (NASDAQ: VVOS), whose approach extends beyond symptom management to address finite anatomical correction.

Robert Sassoon, WTR Senior Healthcare Analyst, joins Shawn Severson, CEO of WTR, to break down the latest clinical readouts in advanced psychedelics — including Compass Pathways’ Phase III progress in treatment-resistant depression, new anxiety data from Helus, and the upcoming milestones that could shape the future of mental health treatment. From durability and dosing models to regulatory momentum and investor implications, this episode explores why 2026 may be a pivotal year for the field.

In this episode of the WTR Healthcare Happenings, we welcome back Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences (NASDAQ: ANIX) who explains why 2026 is shaping up to be a pivotal year for the company. Building on the momentum of 2025, Dr. Kumar walks us through key developments across Anixa’ clinical pipeline and strategic direction. He outlines the company’s plans as its breast cancer vaccine progresses into Phase 2 following strong Phase 1 results. At the same time, he emphasizes the striking efficacy signals emerging from the Phase 1 study of Lira‑Cel, Anixa’ CAR‑T therapy for ovarian cancer, observed in a terminally ill patient population. Dr. Kumar also details key protocol enhancements in the ongoing Phase 1 trial, to help steer the program toward potentially groundbreaking curative outcomes. Finally, supported by Anixa’s capital‑efficient business model, Dr. Kumar notes that the expansion of clinical data in 2026 could drive meaningful opportunities for pharma partnerships and further validate the company’s broader immunotherapy strategy.

In this episode of the WTR Healthcare Happenings, Adam Fraser, COO of Omniscient Neurotechnology—a privately held, Australian‑based but U.S.-focused company pioneering AI‑driven brain mapping—joins Water Tower Research Co‑Founder Tim Gerdeman and Healthcare Analyst Robert Sassoon for a deep dive into the future of clinical connectomics. The discussion explores how Omniscient’s flagship platform, Quicktome, uses advanced AI to transform complex brain data into intuitive, Google‑Maps‑style network visualizations that enhance neurosurgical planning, support coma and mental‑health assessments, and inform broader brain‑care decisions. Fraser also walks through the company’s growth trajectory, funding milestones, and strategy to scale across the U.S. hospital market while laying the groundwork for global expansion and broader neurotech partnerships. The conversation concludes with Omniscient’s long‑term vision to build a comprehensive “brain data economy” capable of powering next‑generation innovations—from BCIs and DBS to emerging solutions like TMS for major psychiatric conditions.

In this episode of the WTR Healthcare Happenings podcast, Rick Pierce, CEO of Decoy Therapeutics (NASDAQ: DCOY), joins Tim Gerdeman, Vice Chair, Co‑Founder, and CMO of Water Tower Research, and Robert Sassoon, WTR’s Healthcare Research Analyst. The conversation explores Decoy’s innovative business model for developing peptide‑conjugate antivirals designed to target multiple respiratory viruses. Pierce discusses how Decoy is navigating the modern era of drug development with a cost‑effective, highly efficient strategy that positions the company as a disruptive force in biotech. Central to this approach is Decoy’s proprietary peptide‑synthesis technology and rapid design‑build‑test cycle, powered by machine learning. He also highlights the importance of Decoy’s strategic partnerships with the Gates Foundation, Google, and NVIDIA in advancing its platform and accelerating development.

In this episode of WTR Healthcare Happenings, Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma (NASDAQ: MDCX), joins Tim Gerdeman and Robert Sassoon to walk through the company’s strategy and market focus. Dr. Bokhari explains how Medicus Pharma acquires mid‑stage drug assets with existing data, reducing development risk and positioning the company for potential partnerships with larger pharmaceutical players.The conversation highlights Medicus Pharma’s two lead programs aimed at major, established markets—including treatments for skin cancer and prostate‑related conditions, both representing large patient populations and significant commercial demand. Dr. Bokhari also discusses how the company is using generative AI to speed decision‑making, along with upcoming milestones and opportunities to secure non‑dilutive funding through out‑licensing.

In this episode of WTR Healthcare Happenings, Dr. Lior Shaltiel, CEO of NurExone Biologic (OTCQB: NRXBF / TSXV: NRX), joins Tim Gerdeman and Robert Sassoon to discuss how the company is positioning itself as a standout early‑clinical‑stage biotech. Dr. Shaltiel breaks down NurExone’s focus on developing a first‑of‑its‑kind, non‑invasive therapy platform aimed at large markets with significant unmet needs, including spinal cord injury and other central nervous system conditions.The conversation explores how NurExone’s approach could open the door to new treatment possibilities, why the company believes its technology has the potential to reshape patient recovery, and what milestones investors should watch as the company advances through early clinical development. Dr. Shaltiel also shares insights into NurExone’s partnership strategy, regulatory path, and how the company is working to build long‑term value in a competitive biotech landscape.

In this episode of the WTR Healthcare Happenings Podcast, Tim Gerdeman and Robert Sassoon speak with Jim Martin, Co‑CEO and CFO of Cocrystal Pharma (NASDAQ: COCP). Martin explains the company’s Nobel Laureate‑developed drug discovery platform, which uses high-resolution crystallography to target viral regions resistant to mutation, enabling broad‑spectrum antivirals. The discussion highlights Cocrystal’s lead candidate, CDI‑988, a dual‑indication antiviral for coronaviruses and noroviruses, with a particular focus on advancing the norovirus program due to high global unmet need. Martin outlines the ongoing human challenge norovirus study at Emory University, CDI‑988’s potential as therapy and prophylactic, and growing U.S. government and military interest. The episode also highlights the company' upcoming milestones, including mid‑2026 top-line data for the CDI-988 human challenge study, and an overview of its broader pipeline, including influenza A and B programs.Best,

In this episode of the WTR Healthcare Happenings Podcast, host Tim Gerdeman and healthcare analyst Robert Sassoon are joined by Dr. Jim Gilligan, President and Chief Science Officer of Entropy Neurodynamics (ASX: ENP), formerly Tryptamine Therapeutics. Dr. Gilligan explains the motivation behind the company’s rebrand and its decision to prioritize three core therapeutic targets: Binge Eating Disorder, Fibromyalgia, and Irritable Bowel Syndrome/abdominal pain. Although Entropy has reported positive Phase 2a results using oral psilocybin across these indications, Dr. Gilligan outlines why the company is shifting its strategy toward developing proprietary IV‑delivered psilocin formulations combined with psychotherapy, beginning with binge eating disorder. The discussion also covers Entropy’s work on real‑time EEG and brain entropy as a potential biomarker, the company’s financing,  regulatory roadmap, and longer‑term expansion opportunities in areas such as PTSD.

In this special Flashcast episode of the WTR Healthcare Happenings podcast, Tim Gerdeman sits down with WTR Healthcare analyst Robert Sassoon to discuss his Initiation of Coverage Report on Anixa Biosciences. Their conversation explores Anixa’s two clinical‑stage programs—one, an innovative CAR‑T cell therapy for terminal ovarian cancer patients, and the other, a breast cancer vaccine designed for both treatment and prevention. They review Phase 1 results, upcoming 2026 milestones, and how Anixa differentiates itself through both its scientific platforms and disciplined financial management.

In this special Flashcast episode of the WTR Healthcare Happenings podcast, Tim Gerdeman and WTR Healthcare analyst Robert Sassoon break down why more than 90% of biotech companies listed on a U.S. exchange choose NASDAQ over the NYSE.

In this episode of WTR Healthcare Happenings, host Tim Gerdeman and analyst Robert Sassoon speak with Eric Poma PhD, CEO of Calidi Biotherapeutics Inc (NYSE American: CLDI).  The discussion focuses on how Calidi is solving the "delivery problem" in cancer treatment, and specifically how to transport cancer-killing oncolytic viruses systemically through the bloodstream without the body’s immune system neutralizing them before they reach the tumor.

In this episode of WTR Healthcare Happenings, host Tim Gerdeman and analyst Robert Sassoon speak with Dwight Egan, CEO of Co-Diagnostics Inc. (NASDAQ: CODX), about the company’s evolution from a pandemic-era PCR testing provider to a diversified molecular diagnostics leader. In our discussion, Egan highlights the Co-DX PCR Pro, a portable, cost-effective device that delivers gold-standard PCR testing outside the lab and explains how its patented Co-Primer multiplexing technology sets it apart from competitors. Our conversation also covers Co-Diagnostics’ “razor-and-blade” business model, its pipeline of testing capabilities targeting high-impact infectious diseases, the role of AI in manufacturing and diagnostic optimization, and the commercial strategies needed to achieve long-term financial success.

In this episode of WTR Healthcare Happenings,  host Tim Gerdeman and analyst Robert Sassoon talk with Apyron CEO Jagi Gill about the company's innovative neurostimulation technology for chronic pain, an all too prevalent affliction affecting millions of people.  Gill explains why Apyron’s patient-focused approach stands out, and outlines the market opportunity and commercialization strategy.

In this episode of WTR Healthcare Happenings, host Tim Gerdeman and analyst Robert Sassoon speak with Shaun Bagai, CEO of RenovoRx (NASDAQ: RNXT). The company is pioneering targeted oncology therapies and commercializing RenovoCath™, an FDA-cleared multi-specialty local drug delivery device for high unmet needs. We discuss the innovation and advantages of its TAMP™ (Trans-Arterial Micro-Perfusion) platform—powered by the proprietary dual-balloon catheter—and how it sets RenovoRx apart in treating hard-to-reach hypovascular tumors like pancreatic cancer. The conversation also covers RenovoCath’s commercialization strategy and key milestones in its Phase 3 clinical trial aimed at proving the platform’s delivery superiority over the current standard of care.

In this WTR Healthcare Happenings Spotlight Flashcast, host Tim Gerdeman sits down with WTR's Healthcare Analyst Robert Sassoon to discuss his recently published initiation of coverage on Vivos Therapeutics (NASDAQ: VVOS). The conversation explores Vivos’ innovative approach to treating obstructive sleep apnea (OSA), the company's transformative shift to a vertically integrated, patient-centric business model, and the significant market opportunity ahead. Tune in for insights on growth strategy, economics of the pivot, and what investors should watch as Vivos reimagines sleep health.

On the latest WTR Healthcare Happenings podcast episode, we welcomed Jan Eryk Umiastowski, CFO of GenSight Biologics (Euronext Paris: SIGHT), a late clinical-stage biopharma company based in Paris, France, primarily focused on developing and commercializing novel disease-modifying gene therapies aimed at reversing vision loss from severe neurodegenerative retinal diseases. He discusses GenSight's development pipeline, what's unique about  the company's approach to gene therapy and upcoming target milestones.

In our latest WTR Healthcare Happenings podcast, we welcome back Jack Lu, Director of Corporate Development at Ainos (NASDAQ: AIMD)  to discuss key takes from the company's recently reported 3Q25 earnings release. He also dives into  Ainos’ latest strategic partnerships with Topco and NEXCOM, its expanding IP moat with seven new patents, and  outlines the roadmap for 2026—commercial scale-up, industrial deployments and expansion plans beyond Asia.

Hear about the latest dynamic developments in the therapeutic psychedelics sector in our WTR Healthcare Happenings Flashcast. Tim Gerdeman, Vice Chair & Co-Founder and Chief Marketing Officer at WTR, and Robert Sassoon, WTR's Senior Healthcare Analyst, discuss the  October's fundraising activity surge; what has contributed to renewed investor confidence; comparisons with the hype-driven cycle of 2021; impact on valuations in the sector; and sustainability of the positive trend going into 2026.  

In this episode of WTR Healthcare Happenings, Anthony Tennyson, CEO and Co-Founder of Solvonis Therapeutics (LSE: SVNS | OTC: SLVNF), joins host Tim Gerdeman, Vice Chair and Co-Founder of Water Tower Research, and analyst Robert Sassoon.The clinical-stage, UK-listed company (LSE: SVNS) focuses on developing novel medicines for high-burden CNS disorders, with its current focus primarily on Alcohol Use Disorder (AUD). Our discussion delves into  Solvonis' lead clinical programs, SVN-001 and SVN-002, that aim to address this major societal problem. Tennyson highlights anticipated upcoming milestones and outlines Solvonis' capital-efficient business model and financial strategy to advance its AUD programs to commercialization. 

In this episode of WTR Healthcare Happenings, Dr. Lior Shaltiel, CEO of NurExone Biologic (TSXV: NRX | OTCQB: NRXBF), and Yoram Drucker, Founder, VP of Business Development, and Active Chairman, join host Tim Gerdeman, Vice Chair and Co-Founder of Water Tower Research, along with WTR Senior Equity Research Analyst Robert Sassoon.The conversation explores NurExone’s groundbreaking exosome-based ExoTherapy platform and its lead candidate ExoPTEN, designed to regenerate damaged neurons following spinal cord and optic nerve injuries—two massive unmet medical markets. Shaltiel and Drucker discuss the company’s remarkable preclinical data showing functional recovery in up to 100% of animal models, the mechanism of action behind their siRNA-loaded exosomes, and why their cell-free, off-the-shelf therapy may become a game-changer for central nervous system repair.They also highlight NurExone’s U.S. manufacturing subsidiary, ExoTop, expected to begin generating revenue in 2026, and share updates on regulatory milestones, cash position, and plans to uplist to a U.S. national exchange.

In this episode of WTR Healthcare Happenings, WTR's Tim Gerdeman, and Robert Sassoon welcomes back Nick Kadysh, Founding CEO and President of PharmAla Biotech (OTCQB: MDXXF). The discussion explores the evolving global regulatory environment for psychedelics—particularly MDMA—the ripple effects of the Lykos Therapeutics FDA Complete Response Letter (CRL) disclosures, and PharmAla’s strategic approach to research, manufacturing, and commercialization of clinical-grade MDMA and next-generation analogues.

In this episode of WTR Healthcare Happenings, host Tim Gerdeman and WTR’s Robert Sassoon speak with Amit Kumar, PhD, CEO of Anixa Biosciences (NASDAQ: ANIX) to discuss t-cells and Anixa's two clinical developments, one involving the modification of CAR-T technology to overcome the challenges of treating solid tumors, specifically ovarian cancer, and the other, an innovative breast cancer vaccine that trains antigen-specific t-cells  to recognize and attack breast cancer cells, especially those from triple-negative breast cancer, the most aggressive form of breast cancer.  Kumar also talks about the company's robust balance sheet and financial strategy to advance Anixa's clinical developments to commercialization.  

We welcome back Veru's CEO Mitch Steiner to our latest WTR Healthcare Happenings podcast. In this podcast, Steiner gives us his thoughts on the latest trends in the rapidly evolving GLP-1 market for weight loss, discusses the data from enobosarm's Phase 2b data, and explains  Veru's obesity drug development strategy in the wake of its recent positive interactions with the FDA.

In this episode of WTR Healthcare Happenings, host Tim Gerdeman and WTR’s Robert Sassoon speak with Marvin Slosman, CEO of InspireMD (NASDAQ: NSPR), to discuss how the company is transforming carotid artery disease treatment with its groundbreaking CGuard® Prime Carotid Stent System. The conversation covers FDA approval, clinical data, market adoption, competitive positioning, and InspireMD’s long-term growth strategy.

In this episode of the WTR Healthcare Happenings Podcast, Water Tower Research’s Tim Gerdeman and Robert Sassoon sit down with Charles Nader, CEO of Doc.com, to discuss the company’s mission to provide free basic telehealth services worldwide. The conversation covers Doc.com’s innovative use of AI and blockchain, strategic partnerships, competitive differentiation, and plans for scaling telemedicine and pharmacy services globally.

In this special Flashcast edition of the WTR Small-Cap Spotlight Podcast, host Tim Gerdeman sits down with Robert Sassoon, Senior Research Analyst at Water Tower Research, to discuss the recent wave of deal activity in the psychedelics sector.Robert breaks down major transactions, including why the AbbVie/Gilgamesh deal marks a potential turning point for the industry, and what these developments could mean for sector valuations going forward.Whether you’re an investor tracking emerging growth sectors or just curious about the rapidly evolving psychedelics market, this quick-hit episode provides the essential insights you need to stay ahead.

In this episode of the WTR Healthcare Happenings podcast, we are joined by Ludwig Enterprises (OTC: LUDG) Co-Founder and Chief Scientific Officer Marvin Hausman MD to talk about the company's innovative and proprietary mRNA genomic technology. Dr. Hausman discusses  how it revolutionizes  early detection of chronic inflammatory-driven diseases like cancer and advances the adoption of personalized medicine.

CEO Brent Lucas of Envoy Medical (NASDAQ: COCH), an innovative hearing health technology company and sole US-domiciled cochlear implant company  joins the WTR Healthcare Happenings podcast to talk about hearing loss, the third most chronic physical condition prevalent in the US, and how  Envoy's innovative device technology can disrupt the hearing solutions market that has long lacked transformative advancements.  Lucas discusses Envoy's two fully implantable hearing solution products, one in the market (Esteem), the only FDA approved middle ear implant for moderate to severe hearing loss, and the other (Acclaim),  a cochlear implant targeting severe to profound hearing loss which is currently in the advanced stages of clinical development (Acclaim), the competitive landscape and the commercial opportunities. 

In our latest WTR Healthcare Spotlight podcast, we were joined by Jack Lu,  Director of corporate Development at Ainos (NASDAQ: AIMD) to discuss the company's pioneering smell digitization AI technology platform, AI Nose; diversification of the platform's penetration across multiple verticals through strategic partnerships;  commercialization opportunities and expansion goals.

In this episode of WTR Healthcare Spotlight podcast, we are joined by Lisata Therapeutics' (NASDAQ: LSTA) CEO David Mazzo, PhD and Chief Medical Officer Kristen Buck, MD to talk about, Certepetide, the company's novel solid tumor targeting and penetration technology with tumor microenvironment modifying properties.  We also dive into the recently reported positive preliminary results from Lisata's lead program (Ascend), a Phase 2b study investigating Certepetide for metastatic pancreatic ductal adenocarcinoma (the most common and aggressive form of pancreatic cancer), Lisata's partnerships, and upcoming milestones.  

In our first rebranded WTR Healthcare Spotlight, Cybin CEO Doug Drysdale joins Water Tower Research’s Tim Gerdeman and Senior Analyst Robert Sassoon to discuss the company's non-traditional financing strategy as it continues to advance its development pipeline. Drysdale also probes into data that highlight advantages that distinguish Cybin's lead program CYB003 from other aspiring late-stage novel therapies in the depression treatment landscapeCybin (NYSE: CYBN) is a late-stage clinical development company focused on developing novel psychedelic-based neuropsychiatric compounds. Its two lead candidates, targeting two of the most pervasive mental health disorders, are psilocin-based CYB003 for Major Depressive Disorder (MDD), currently being dosed in a Phase 3 program, and DMT-based CYB004 for General Anxiety Disorder (GAD) which is wrapping up a Phase 2 study.  

In this episode of the WTR Biotech Spotlight, Water Tower Research’s Tim Gerdeman is joined by Nick Kadysh, Founding CEO and President of Toronto-headquartered Life Sciences company, PharmAla Biotech (CSE: MDMA; OTCQB: MDXXF),and WTR Senior Analyst Robert Sassoon for an insightful discussion on arguably the two main topics that are currently concentrating the minds of  biotech industry folk: The implications of the Trump Administration's FDA reforms and  AI's role in reshaping the industry.With over a decade of experience as a Public Affairs and Regulatory expert, Nick Kadysh founded PharmAla in 2020 to focus on the manufacturing and development of MDMA and MDMA-related molecules. Kadysh is also a prominent spokesman for the deployment of AI in drug discovery, 

Trevi Therapeutics CEO Jennifer Good joins us on this week’s WTR Biotech Spotlight to talk about the recent and impressive clinical data for Haduvio in IPF-associated chronic cough and refractory chronic cough. We discuss Haduvio’s unique mechanism and unscheduled status, supported by a human abuse study. Listen to learn more about Trevi Therapeutics and how Haduvio could change the chronic cough treatment landscape.

In this episode of the WTR Biotech Spotlight, Water Tower Research’s Tim Gerdeman is joined by Dr. Chris Witowski, CEO of Psilera, and WTR Senior Analyst Robert Sassoon for an insightful discussion on the company’s pioneering work in neuroplastogen drug development and delivery technologies.Dr. Chris  Witowski, CEO and Co-Founder of Psilera, an early-stage biotech company focused on developing next-generation neuroplastegens for neurological and neuropsychiatric disorders, shares his thoughts and insights on the evolution of biomarkers in the neurosciences, the latest developments and trends in CNS-focused biomarkers and the potentially transformative impact they will have on the CNS treatment landscape.Tune in to learn more about Psilera’s vision for the future of neurotherapeutics and how the company is working to transform the treatment landscape for CNS disorders.

On this week’s WTR Biotech Spotlight, we speak with Apimeds CEO Erik Emerson about the newly NYSE listed company and the development of Apitox, a purified honeybee venom, for knee osteoarthritis and multiple sclerosis. We discuss the therapeutic properties of bee venom and the clinical/regulatory plans to bring Apitox to the US market. Listen to learn more about Apimeds and its novel approach to treat inflammatory pain.

CEO of Zomedica (OTCQB: ZOMDF)  Larry Heaton joins WTR's Tim Gerdeman and Robert Sassoon in this week's WTR Small-Cap Spotlight episode. Since 2021 Zomedica has expanded its suite of innovative offerings from one product to six. All are proprietary, highly differentiated either diagnostic or therapeutic devices, to help veterinarians not only improve the quality of care for pets, but also importantly to help improve the efficiency of how vets themselves operate to maximize the profitability of their practices. Heaton provides a concise overview of Zomedica’s products,  explains how they differentiate themselves from what exists in the market today and the company’s growth opportunities.